Page 1 of 1 FORM PTO-1449(Modified) ATTY. DOCKET NO. B0801/7155 SERIAL NO. 09/405,735 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANTS APPLICANT Gerald B. Pier INFORMATION DISCLOSURE STATEMENT FILING DATE September 24, 1999 GROUP 1646 **U.S. PATENT DOCUMENTS** Exam Ref Sub FILING DATE

ı Des	Document No.	Date	Name	Class	Class	If Appropriate
DF.G	5,240,846	08/31/93	Collins et al	435	240	
11	-5,407,796	04/18/95	Cutting et al.			
4	5,434,086	07/18/95	Collins et al.	436	125	
	<u> </u>					
	 		FOREIGN PATENT DOCUMENTS			
0	Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No
F.G	WO95/28494	10/26/95	TARGETED GENETICS CORPORATION			
1/	WO95/25796	09/28/95	UNIVERSITY OF IOWARES FOUND			
1 0	WO95/13365	05/18/95	TARGETED GENETICS CORPORATION			
14	WO95/06743	03/09/95	UAB RESEARCH FOUNDATION			
IV	W094/25607	11/10/94				
N	W094/04671	03/03/94	GENZYME CORPORATION			
Λ	WO94/04669	03/03/94	MEDICAL RESEARCH COLINCIL			
N	WO93/24641	12/09/93	DEPT, OF HEALTH & HUMAN SERV			
[1	WO93/17040	09/02/93				
10	WO93/12240	06/24/93				
<u>// // </u>	W091/02796	03/07/91				
	F.G H F.G N N N	Country & Doc. No. (11) F.G W095/25796 W095/13365 W094/04669 W093/17040 W093/17040	Country & Date (43) Country & Pub. Date (43) Country & Pub. Date (43) Country & Doc. No. (11) Country & Dot. (43) Country & Dot. (S	Solution Solution	Sub Sub

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.) Pier, G.B., et al., "ROLE OF MUTANT CFTR IN HYPERSUSCEPTIBILITY OF CYSTIC FIBROSIS PATIENTS TO LUNG INFECTIONS', SCIENCE, 1996, 271:64-67 Masoud, H., et al., "STRUCTURAL ELUCIDATION OF THE LIPOPOLYSACCHARIDE CORE REGION OF THE O-CHAIN-DEFICIENT MUTANT STRAIN A28 FROM PSEUDOMONAS AERUGINOSA SEROTYPE 06 (INTER-IJ NATIONAL ANTIGENIC TYPING SCHEME), JOURNAL OF BACTERIOLOGY, 1995, 177:23:6718-6726 Imundo, L., et al., 'CYSTIC FIBROSIS EPITHELLIAL CELLS HAVE A RECEPTOR FOR PATHOGENIC BAC-11 TERIA ON THEIR APICAL SURFACE", PROC. NATL. ACAD., 1995, 92:3019-3023 Zar, H., et al., "BINDING OF PSEUDOMONAS AERUGINOSA TO RESPIRATORY EPITHELIAL CELLS FROM * PATIENTS WITH VARIOUS MUTATIONS IN THE CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR* THE JOURNAL OF PEDIATRICS, 1995, 126:2:230-233 * Masoud, H., et al., "GENERAL STRATEGY FOR STRUCTURAL ANALYSIS OF THE OLIGOSACCHARIDE REGION OF REGION OF LIPOOLIGOSACCHARIDES. STRUCTURE OF THE OLIGOSACCHARIDE COMPONENT OF // PSEUDOMONAS AERUGINOSA IATS SEROTYPE 06 MUTANT R5 ROUGH-TYPE LIPOPOLYSACCHARIDE". BIOCHEMISTRY, 1994, 33:10568-10578. DeKievit, T.R., et al., MONOCLONAL ANTIBODIES THAT DISTINGUISH INNER CORE, OUTER CORE. AND LIPID A REGIONS OF PSEUDOMNAS AERUGINOSA LIPOPOLYSACCHARIDE", JOURNAL OF BAC-TERIOLOGY, 1994, (DEC) 7129-7139 Boucher, R.C., et al., 'CLINICAL PROTOCOL-GENE THERAPY FOR CYSTIC FIBROSIS USING EI-DELETED N ADENOVIRUS:A PHASE I TRIAL IN THE NASEL CAVITY", HUMAN GENE THERAPY, 1994, 5:615-639

422068. I Soly Sein

1/25/04